China Bozza Development Holdings Limited (1069) AI Stock Analysis

• Market Cap: HK$31.91M
• Dividend Yield: N/A
• Average Volume (3M): 417.79K
• Price to Earnings (P/E): 1.3
• Beta (1Y): 1.18
• Revenue Growth: 88.72%
• EPS Growth: -91.59%
• Country: HK
• Employees: 33
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Paper, Lumber & Forest Products
• EPS (TTM): N/A
• Shares Outstanding: 102,924,220
• 10 Day Avg. Volume: 214,500
• 30 Day Avg. Volume: 417,794
• PEG Ratio: -0.01
• Price to Book (P/B): 1.30
• Price to Sales (P/S): 0.33
• P/FCF Ratio: -33.74
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: HK$0.30 ▼(-34.57% Downside)
• Action: Reiterated Date: 03/20/26
• Date: Action: Reiterated 03/20/26

The score is held down primarily by weak financial quality (profitability issues, high leverage, and negative free cash flow) and bearish technicals with the stock in a broad downtrend. A very low P/E provides some valuation support but does not outweigh the operational and balance-sheet risks.

Positive Factors

Revenue Growth

Sustained double‑digit revenue growth demonstrates durable demand for the company’s products and expanding market traction. Over a 2–6 month horizon this growth supports scale economies and gives management room to prioritize margin recovery, reinvest in operations, and negotiate supplier/ customer terms.

Positive Operating Cash Flow

Positive operating cash flow indicates the core business currently generates cash from operations, providing a recurring source to fund working capital and near‑term needs. This reduces reliance on short‑term financing and supports operational continuity while management works on improving free cash flow.

Lean Operating Footprint

A small employee base implies a lean cost structure that can allow revenue increases to flow more directly to margins if operational inefficiencies are fixed. Over months, a compact organization can scale selectively, control overhead growth, and adapt faster to demand or supply shifts.

Negative Factors

High Leverage

Significant leverage strains financial flexibility and raises refinancing and interest‑rate exposure. Over a multi‑month horizon, high debt limits the company’s ability to invest in margin improvement or weather shocks, increasing liquidity risk and the chance of covenant pressure or costly external financing.

Negative Free Cash Flow

Negative free cash flow means capital expenditures or working capital needs exceed cash generated, forcing reliance on debt or equity to fund growth. Persisting FCF deficits erode resilience, constrain capital allocation, and raise the probability of dilution or increased leverage in the coming months.

Weak Profitability

Negative operating margins point to structural cost or pricing issues that prevent the firm from converting sales into sustainable profits. Without sustained margin improvement, revenue growth alone won't translate to shareholder returns, leaving the firm vulnerable to margin compression or prolonged unprofitability.

China Bozza Development Holdings Limited Business Overview & Revenue Model

Company Description

China Health Technology Group Holding Co., Ltd. is an investment company, which engages in the business of forestry management. It engages in the plantation, logging, and sale of timbre related products. The company was founded on October 8, 2009 and is headquartered in Shenzhen, China.

China Bozza Development Holdings Limited Financial Statement Overview

Summary

Strong revenue growth is a clear positive, but overall fundamentals are weak due to negative EBIT/EBITDA margins, high leverage (elevated debt-to-equity and low equity ratio), and negative free cash flow that raises liquidity and financing risk.

Income Statement

The company has shown significant revenue growth of 63.14% in the latest period, which is a positive indicator. However, the negative EBIT and EBITDA margins indicate operational inefficiencies, and the net profit margin is volatile, suggesting instability in profitability.

Balance Sheet

The balance sheet shows a high debt-to-equity ratio, indicating significant leverage, which poses financial risk. The equity ratio is low, and the return on equity is inconsistent, reflecting potential challenges in generating returns for shareholders.

Cash Flow

The operating cash flow is positive, which is a strength, but the free cash flow is negative, indicating potential liquidity issues. The free cash flow growth rate is negative, suggesting declining cash generation capabilities.

Breakdown	TTM	Jun 2024	Jun 2024	Dec 2022	Jun 2022	Dec 2020
Income Statement
Total Revenue	94.60M	97.39M	47.61M	58.72M	6.76M	6.67M
Gross Profit	8.62M	8.87M	1.90M	11.51M	0.00	6.67M
EBITDA	-7.74M	-7.74M	208.39M	-42.17M	-9.85M	-48.36M
Net Income	24.03M	24.52M	200.01M	-10.80M	-18.90M	-268.54M
Balance Sheet
Total Assets	225.04M	191.09M	178.17M	140.64M	93.52M	491.54M
Cash, Cash Equivalents and Short-Term Investments	4.92M	2.68M	3.23M	4.33M	1.11M	134.00K
Total Debt	127.45M	115.23M	119.11M	356.77M	321.97M	333.44M
Total Liabilities	173.86M	166.22M	165.20M	457.35M	400.15M	369.48M
Stockholders Equity	51.18M	24.87M	12.96M	-316.71M	-306.63M	122.06M
Cash Flow
Free Cash Flow	1.77M	-959.71K	28.63M	22.16M	-466.00K	-5.58M
Operating Cash Flow	1.77M	37.43M	28.86M	23.44M	-466.00K	-5.58M
Investing Cash Flow	-6.15M	-38.34M	-26.49M	-23.26M	2.00K	-410.00K
Financing Cash Flow	3.83M	2.29M	-3.47M	3.04M	-249.00K	-3.29M

China Bozza Development Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.46
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1069, the sentiment is Negative. The current price of 0.46 is above the 20-day moving average (MA) of 0.39, above the 50-day MA of 0.41, and above the 200-day MA of 0.44, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 24.55 is Positive, neither overbought nor oversold. The STOCH value of 30.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1069.

China Bozza Development Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2002	64 Neutral	HK$1.31B	5.14	3.55%	3.45%	-5.66%	-56.96%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
0794	49 Neutral	HK$81.12M	-2.98	0.85%	―	-5.06%	―
1812	46 Neutral	HK$6.58B	-0.27	―	―	-76.55%	-966.54%
3363	46 Neutral	HK$167.50M	19.62	2.11%	6.11%	0.80%	81.27%
0731	45 Neutral	HK$224.92M	-1.62	0.19%	―	-9.44%	―
1069	44 Neutral	HK$31.91M	1.32	63.18%	―	88.72%	-91.59%

China Bozza Development Holdings Limited Corporate Events

China Health Technology Group Posts Modest Profit Growth on Higher Revenue

China Health Technology Group reported interim unaudited revenue of RMB34.4 million for the six months ended 31 December 2025, up from RMB31.1 million a year earlier, as gross profit rose to RMB4.1 million from RMB2.8 million. Profit for the period edged up to RMB5.3 million from RMB5.0 million, supported by stable other gains and lower administrative expenses, while finance costs increased and basic earnings per share declined on a restated basis.

Total comprehensive income slipped to RMB5.4 million from RMB6.4 million, mainly due to a smaller positive exchange translation effect compared with the previous period. The figures indicate modest top-line growth and resilient profitability despite higher financing costs, suggesting that the group is maintaining operational efficiency while facing currency fluctuations and capital cost pressure that stakeholders will need to monitor.

The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.45 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.

China Health Technology Schedules Board Meeting to Review Interim Results and Dividend

China Health Technology Group Holding Company Limited has scheduled a board meeting for 27 February 2026. The board will review and approve the Group’s interim results for the six months ended 31 December 2025 and consider whether to declare an interim dividend, signaling a forthcoming update on the company’s financial performance and potential shareholder returns.

The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.45 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.

China Health Technology Group bolsters board with two new director appointments

China Health Technology Group Holding Company Limited has strengthened its leadership team with the appointment of Ms. Cao Xiying as an executive director effective 15 January 2026, bringing project management and sales and marketing experience from internet finance and media technology sectors; she will serve an initial one-year term with remuneration aligned to market levels. The company has also named Mr. Li Liangjie as an independent non-executive director, adding over 15 years of sales management expertise and nearly a decade of online marketing experience in the health and wellness industry, including his role at Henan Yuhuan Health Technology Group; these appointments are expected to enhance the board’s governance, marketing capabilities and sector-specific insight, while ensuring compliance with Hong Kong listing requirements on board and committee composition.

The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.45 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.

China Health Technology Details Board and Committee Structure

China Health Technology Group Holding Company Limited has announced the current composition of its board of directors and the allocation of roles across its key governance committees. Chairman and CEO Ms. Bu Xue serves as an executive director, alongside executive director Ms. Cao Xiying, while independent non-executive directors Mr. Chau Wing Nam, Ms. Liu Shuhua and Mr. Li Liangjie provide oversight, with Mr. Chau chairing the Audit, Remuneration and Nomination committees. The disclosure underscores the company’s emphasis on independent oversight and committee-based governance, a structure that may bolster investor confidence in its board independence and internal control framework.

The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.45 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.

China Health Technology Clarifies AGM Poll Results and Board Committee Heading

China Health Technology Group Holding Company Limited has issued a supplemental announcement correcting clerical errors in the disclosed poll results for two ordinary resolutions at its 31 December 2025 annual general meeting, specifically those relating to authorising the board to fix directors’ remuneration and to re-appoint the company’s auditor, Jon Gepsom CPA Limited, and authorise the board to fix its remuneration; the corrected figures confirm both resolutions were passed with 100% of votes cast in favour. The company also rectified a mislabelled heading regarding changes in board committee composition, clarifying that it pertains to the composition of all board committees rather than only the nomination committee, while emphasising that all other information from the original announcement remains unchanged, thereby seeking to reassure investors about the accuracy of its governance disclosures.

The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.46 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.

China Health Technology Wins Full Shareholder Backing for AGM Resolutions, New Share Scheme and Capital Mandates

Shareholders of China Health Technology Group Holding Company Limited approved all resolutions at the 31 December 2025 annual general meeting, including adoption of the 2025 financial statements, director remuneration, reappointment of Jon Gepsom CPA Limited as auditor, and general mandates for the board to issue up to 20% and repurchase up to 10% of the company’s share capital, as well as an extension mandate and the adoption of a new share scheme. The results, all passed by poll with 100% support on votes cast, also confirmed board changes through the re-election or rejection of certain directors and signalled continued support for the company’s capital management flexibility and equity-based incentive arrangements, with implications for future share issuance and governance structure; the company simultaneously disclosed pending changes to the chairman role, board committees and a period of non-compliance with listing rules, underscoring ongoing governance adjustments closely watched by investors.

The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.46 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.

China Health Technology Group Sets Out Board and Committee Structure

China Health Technology Group Holding Company Limited has announced the current composition of its board of directors, naming Ms. Bu Xue as executive director, chairman and chief executive officer, alongside independent non-executive directors Mr. Chau Wing Nam and Ms. Liu Shuhua. The company also clarified the structure and membership of its three main board committees, with Mr. Chau chairing the audit, remuneration and nomination committees, and Ms. Bu and Ms. Liu serving as members, underscoring the firm’s governance framework and the role of independent oversight in its board operations.

The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.46 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.